Skip to main content

MAXCYTE, INC.

For the period ended Mar 31, 2026. Filed May 13, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 13, 2026

MXCT$1.13-13.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

​​​​​​​
​ · ​ ​ ​ · Three Months Ended March 31,
​ · ​ · 2026 · ​ ​ ​ · 2025
Revenue​$9,651​$10,390
Cost of goods sold​1,569​1,497
Gross profit​8,082​8,893
​​​​​​​
Operating expenses:​​​​
Research and development​3,857​5,903
Sales and marketing​3,428​5,698
General and administrative​5,966​8,526
Depreciation and amortization​​1,016​​1,061
Total operating expenses​14,267​21,188
Operating loss​(6,185)​(12,295)
​​​​​​​
Other income:​​​​
Interest income​1,435​2,034
Total other income​1,435​2,034
Loss before income taxes​​(4,750)​​(10,261)
Provision for income taxes​​—​​—
Net loss​$(4,750)​$(10,261)
Basic and diluted net loss per share​$(0.04)​$(0.10)
Weighted-average shares outstanding, basic and diluted​106,875,087​105,950,480
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.